Medtronic Plc Hits New 52-Week Low at USD 77.17

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 77.17 as of May 6, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 6.66%, contrasting sharply with the S&P 500's impressive gain of 31.36% during the same period. The company's market capitalization stands at USD 113,290 million, categorizing it as a large-cap entity. Medtronic's price-to-earnings (P/E) ratio is currently at 20.00, while its dividend yield is noted at 3.20%. The firm maintains a low debt-to-equity ratio of 0.43, indicating a conservative approach to leveraging. Despite the recent price movement, Medtronic has shown some positive operational metrics, including a record operating cash flow of USD 7,146 million and a return on capital employed (ROCE) of 9.72%. However, the company has faced challenges in long-term growth, with operating profit increasing at an annual rate of 9.68% over the past five years. The stock's performance continues to be closely monitored as it navigates these market dynamics.